SEPTIN9 and colorectal carcinoma: The circulating Septin 9 methylated DNA demonstrated 73.3% sensitivity for CRC detection, comparable with that of the fecal immunochemical test (68.0%) [31], and is FDA-approved as an emerging, more accessible blood-based test option [29].